½ÃÀ庸°í¼­
»óǰÄÚµå
1463657

ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : Áö¿ª ºÐ¼® - Á¦Ç°º°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(-2030³â)

North America Cerebrospinal Fluid Management Market Forecast to 2030 - Regional Analysis - by Product (CSF Shunts and CSF Drainage Systems) and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 80 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº 2022³â 8¾ï 796¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 12¾ï 4,249¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 5.5%·Î ÃßÁ¤ ÇÕ´Ï´Ù.

³úô¼ö¾× ´©Ãâ »ç·Ê Áõ°¡°¡ ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀ» µÞ¹Þħ

Journal of Neurosurgery¿¡ µû¸£¸é, ¼¼°è¿¡¼­´Â ¿¬°£ 6,900¸¸ ¸í ÀÌ»óÀÌ ¿Ü»ó¼º ³ú ¼Õ»óÀ¸·Î °íÅë¹Þ°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ³ú¿Í ô¼öÀÇ ¼Õ»óÀº ¼ºÀÎÀÇ ³úô¼ö¾×(CSF) ´©ÃâÀÇ °¡Àå ÈçÇÑ ¿øÀÎÀ̸ç CSF °ü¸®°¡ ÇÊ¿äÇÕ´Ï´Ù. ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­¿Í °Ç°­¿¡ ÇØ·Î¿î »ýȰ ½À°üÀÌ ÁÖ¿ä ¿øÀÎ ÀÎ °íÇ÷¾Ðµµ ¼ºÀΰú ³ëÀÎÀÇ ¼ö¾× ´©ÃâÀÇ ÇöÀúÇÑ ¿øÀÎÀÔ´Ï´Ù. ¸¶Âù°¡Áö·Î °íÇ÷¾ÐÀº ³ëÀο¡°Ô ¸¹À¸¸ç ±Ã±ØÀûÀ¸·Î Ư¹ß¼º µÎ°³ ³»¾Ð Ç×ÁøÁõ(IIH)ÀÇ À§ÇèÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ³ë³â Àα¸ Áõ°¡´Â ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀÇ ¼ºÀå°ú °ü·ÃµÉ ¼ö ÀÖ½À´Ï´Ù.

¼öµÎÁõÀÇ ¹ß»ý·üÀº Àü ¼¼°èÀûÀ¸·Î ÇöÀúÇÏ°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼öµÎÁõÀÇ ¹ß»ý·üÀº ³ë³â Àα¸¿¡¼­ °¡Àå ³ô°í, ƯÈ÷ ¼Ò¾Æ Àα¸¿¡¼­´Â ¼ºÀο¡ ºñÇØ ³ô½À´Ï´Ù. ¹Ì±¹ ±¹¸³ÀÇÇÐ µµ¼­°ü(NLM)ÀÌ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é ¼öµÎÁõ ¼¼°è À¯º´·üÀº 10¸¸¸í´ç ¾à 85¸íÀÔ´Ï´Ù. °°Àº Ãâó¿¡ µû¸£¸é ¼Ò¾ÆÀÇ À¯º´·üÀº 10¸¸¸í´ç 88¸íÀÎ ¹Ý¸é ¼ºÀο¡¼­´Â 10¸¸¸í´ç 11¸í, ³ëÀο¡¼­´Â 10¸¸¸í´ç 175¸íÀÔ´Ï´Ù. ¶ÇÇÑ Àú,Á߼ҵ汹ÀÇ ¼öµÎÁõ ÀÌȯÀ²Àº Ãâ»ý 10¸¸¸í´ç 123¸íÀÎ ¹Ý¸é °í¼Òµæ±¹°¡¿¡¼­´Â 79¸íÀÔ´Ï´Ù. ¼ö¾× ¼ÇÆ®¿Í ¹è¼ö ½Ã½ºÅÛÀº ¸ðµç ¿¬·É´ëÀÇ ¼öµÎ »ç·Ê¿¡ ÀûÇÕÇÑ Ä¡·á¹ýÀÔ´Ï´Ù. ±×·¯¹Ç·Î, ¼ö¾× ´©Ãâ Áõ·Ê Áõ°¡´Â ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå °³¿ä

ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ¹Ì±¹ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ÀÌ Áö¿ª ½ÃÀåÀº ¼öµÎÁõ, ¿Ü»ó¼º ³ú¼Õ»ó, ±âŸ ½Å°æÁúȯÀÇ ¹ß»ý·ü Áõ°¡, ±Þ¼ÓÇÑ ±â¼ú Çõ½Å, ½ÅÈï±¹ ½ÃÀåÀÇ ÀÎÇÁ¶ó Á¤ºñ µî¿¡ ÀÇÇØ ¿¹Ãø±â°£ µ¿¾È¿¡µµ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(US$Mn)

ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀÇ ¼¼ºÐÈ­

ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº Á¦Ç°, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº CSF ¼ÇÆ®¿Í CSF ¹è¼ö ½Ã½ºÅÛÀ¸·Î À̺е˴ϴÙ. 2022³â¿¡´Â CSF ¼ÇÆ® ºÎ¹®ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î º¸¸é ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº 2022³â ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.

Argi Group Health Services Ltd Sti, B. Braun SE, BeckerSmith Medical Inc, Integra LifeSciences Holdings Corp, Medtronic Plc, Natus Medical Inc, Sophisa SA, Spiegelberg GmbH ´ë±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀÇ Á¤¼¼

  • ºÏ¹Ì PEST ºÐ¼®

Á¦5Àå ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå- ÁÖ¿ä »ê¾÷¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ³úô¼ö¾× ´©Ãâ Áõ·Ê Áõ°¡
    • ¼ö¾× °ü¸® Á¦Ç° °³¹ß
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °íÀåÀ̳ª ¿ÀÀÛµ¿ÀÇ À§Çè
  • ½ÃÀå ±âȸ
    • ½Å°æÁúȯ Ä¡·á¿¡ À־ÀÇ ¼ö¾× °ü¸®¿¡ ´ëÇÑ ÁÖ¸ñÀÇ °íÁ¶
  • ÇâÈÄÀÇ µ¿Çâ
    • ½º¸¶Æ® ³úô¼ö¾× ¼ÇÆ® °³¹ß
  • ¿µÇ⠺м®

Á¦6Àå ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå-ºÏ¹Ì ½ÃÀå ºÐ¼®

  • ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå ¼öÀÍ(2022³â-2030³â)

Á¦7Àå ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : Á¦Ç°º°

  • ½ÃÀå¼öÀÍ Á¡À¯À²(2022³â, 2030³â)
  • ¼ö¾× ¼ÇÆ®
  • ¼ö¾× ¹è¼ö ½Ã½ºÅÛ

Á¦8Àå ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : ÃÖÁ¾ »ç¿ëÀÚº°

  • ½ÃÀå¼öÀÍ Á¡À¯À²(2022³â, 2030³â)
  • º´¿ø
  • Áø·á¼Ò
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦9Àå ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ±¹°¡º°
  • ¹Ì±¹
  • ij³ª´Ù
  • ¸ß½ÃÄÚ

Á¦10Àå ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ¾÷°è Á¤¼¼

  • ºÏ¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå¿¡¼­ÀÇ ¼ºÀå Àü·«(2020³â-2023³â)
  • ¹«±âÀû ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Medtronic Plc
  • Integra LifeSciences Holdings Corp
  • B. Braun SE
  • Argi Group Health Services Ltd Sti
  • Sophysa SA
  • BeckerSmith Medical Inc
  • Natus Medical Inc
  • Spiegelberg GmbH & Co KG

Á¦12Àå ºÎ·Ï

BJH 24.05.23

The North America cerebrospinal fluid management market was valued at US$ 807.96 million in 2022 and is expected to reach US$ 1,242.49 million by 2030; it is estimated to grow at a CAGR of 5.5% from 2022 to 2030.

Increasing Cases of Cerebrospinal Fluid Leaks Fuels the North America Cerebrospinal Fluid Management Market

According to the Journal of Neurosurgery, more than 69 million people globally are estimated to suffer from traumatic brain injuries annually. Brain and spinal injuries are the most common causes of cerebrospinal fluid (CSF) leaks in adults, necessitating CSF management. High blood pressure, majorly caused due to a shift in lifestyle and unhealthy habits, is another notable cause of CSF leaks among adults and elderlies. Similarly, high blood pressure is common in elderly people, which ultimately leads to an increasing risk of idiopathic intracranial hypertension (IIH). Thus, the growing geriatric population can be associated with the growth of the North America cerebrospinal fluid management market.

The incidence of hydrocephalus is growing significantly across the world. The occurrence of hydrocephalus is highest in the geriatric population; notably, it is higher in the pediatric population compared to adults. According to an article published by the National Library of Medicine (NLM), the global prevalence of hydrocephalus is ~85 per 100,000 individuals. Per the same source, the prevalence rate in the pediatric population is ~88 per 100,000 whereas the rate is ~11 per 100,000 in adults and ~175 per 100,000 in the geriatric population. Further, the incidence rate of hydrocephalus in low- and medium-income countries is ~123 per 100,000 births whereas the rate in high-income countries is 79 per 100,000 births. The CSF shunts and drainage systems are the treatment options suitable for hydrocephalus cases diagnosed in people from all age groups. Hence, an increase in CSF leak cases boosts the growth of the North America cerebrospinal fluid management market.

North America Cerebrospinal Fluid Management Market Overview

The North America cerebrospinal fluid management market is segmented into the US, Canada, and Mexico. The US held the largest share of the market in this region. The market in this region is expected to continue its dominance during the forecast period due to the increasing hydrocephalus, traumatic brain injury, and other neurological condition incidences; rapid technological innovations; and developing healthcare infrastructure.

North America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)

North America Cerebrospinal Fluid Management Market Segmentation

The North America cerebrospinal fluid management market is segmented into product, end user and country.

Based on product, the North America cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. The CSF shunts segment held a larger market share in 2022.

Based on end user, the North America cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022.

Based on country, the North America cerebrospinal fluid management market is segmented into the US, Canada, and Mexico. The US dominated the North America cerebrospinal fluid management market share in 2022.

Argi Group Health Services Ltd Sti, B. Braun SE, BeckerSmith Medical Inc, Integra LifeSciences Holdings Corp, Medtronic Plc, Natus Medical Inc, Sophysa SA, and Spiegelberg GmbH & Co KG are some of the leading companies operating in the North America cerebrospinal fluid management market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Cerebrospinal Fluid Management Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis

5. North America Cerebrospinal Fluid Management Market - Key Industry Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increasing Cases of Cerebrospinal Fluid Leaks
    • 5.1.2 Developments in CSF Management Products
  • 5.2 Market Restraints
    • 5.2.1 Risk of Failure and Malfunctioning
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Focus on CSF Management in Neurological Disease Treatments
  • 5.4 Future Trends
    • 5.4.1 Development of Smart Cerebrospinal Fluid Shunts
  • 5.5 Impact Analysis:

6. Cerebrospinal Fluid Management Market - North America Market Analysis

  • 6.1 North America Cerebrospinal Fluid Management Market Revenue (US$ Mn), 2022 - 2030

7. North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 - by Product

  • 7.1 Overview
  • 7.2 North America Cerebrospinal Fluid Management Market Revenue Share, by Product 2022 & 2030 (%)
  • 7.3 CSF Shunts
    • 7.3.1 Overview
    • 7.3.2 CSF Shunts: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.3 Ventriculoperitoneal Shunts
      • 7.3.3.1 Overview
      • 7.3.3.2 Ventriculoperitoneal Shunts: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.4 Ventriculoatrial Shunts
      • 7.3.4.1 Overview
      • 7.3.4.2 Ventriculoatrial Shunts: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.5 Ventriculopleural Shunts
      • 7.3.5.1 Overview
      • 7.3.5.2 Ventriculopleural Shunts: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.6 Lumboperitoneal Shunts
      • 7.3.6.1 Overview
      • 7.3.6.2 Lumboperitoneal Shunts: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 CSF Drainage Systems
    • 7.4.1 Overview
    • 7.4.2 CSF Drainage Systems: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.4.3 External Ventricular Drainage (EVD) Systems
      • 7.4.3.1 Overview
      • 7.4.3.2 External Ventricular Drainage (EVD) Systems: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.4.4 Lumbar Drainage (LD) Systems
      • 7.4.4.1 Overview
      • 7.4.4.2 Lumbar Drainage (LD) Systems: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 - by End User

  • 8.1 Overview
  • 8.2 North America Cerebrospinal Fluid Management Market Revenue Share, by End User 2022 & 2030 (%)
  • 8.3 Hospitals
    • 8.3.1 Overview
    • 8.3.2 Hospitals: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Clinics
    • 8.4.1 Overview
    • 8.4.2 Clinics: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Ambulatory Surgical Centers
    • 8.5.1 Overview
    • 8.5.2 Ambulatory Surgical Centers: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: North America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Cerebrospinal Fluid Management Market - Country Analysis

  • 9.1 Overview
      • 9.1.1.1 North America Cerebrospinal Fluid Management Market, by Country
      • 9.1.1.2 US
        • 9.1.1.2.1 Overview
        • 9.1.1.2.2 US: North America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.2.3 US: North America Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.2.3.1 US: North America Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.2.3.2 US: North America Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.2.4 US: North America Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.3 Canada
        • 9.1.1.3.1 Overview
        • 9.1.1.3.2 Canada: North America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.3.3 Canada: North America Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.3.3.1 Canada: North America Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.3.3.2 Canada: North America Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.3.4 Canada: North America Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.4 Mexico
        • 9.1.1.4.1 Overview
        • 9.1.1.4.2 Mexico: North America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.4.3 Mexico: North America Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.4.3.1 Mexico: North America Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.4.3.2 Mexico: North America Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.4.4 Mexico: North America Cerebrospinal Fluid Management Market, by End User

10. North America Cerebrospinal Fluid Management Market -Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in The North America Cerebrospinal Fluid Management Market, 2020-2023
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Organic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Medtronic Plc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Integra LifeSciences Holdings Corp
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 B. Braun SE
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Argi Group Health Services Ltd Sti
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Sophysa SA
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 BeckerSmith Medical Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Natus Medical Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Spiegelberg GmbH & Co KG
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦